✦ LIBER ✦

192Dose-reduced conditioning with fludarabine/melphalan followed by allogeneic stem cell transplantation for patients with advanced stage II/III multiple myeloma

✍ Scribed by N.M. Kröger; A. Shimoni; A. Nagler; H.G. Sayer; R. Schwerdtfeger; M. Kiehl; G. Wittkowsky; H. Wandt; H. Renges; F. Ayuk; T. Zabelina; A.R. Zander

Book ID: 117728190
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 137 KB
Volume: 9
Category: Article
ISSN: 1083-8791
DOI: 10.1016/s1083-8791(03)80185-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk-factors of melphalan/fludarabine do

Risk-factors of melphalan/fludarabine dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ N. Kroger; J.A. Perez-Simon; H. Myint; H. Klingemann; A. Shimoni; A. Nagler; R. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Melphalan 220 mg/m2 followed by peripher

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

✍ Moreau, P; Milpied, N; Mahé, B; Juge-Morineau, N; Rapp, M-J; Bataille, R; Harous 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 44 KB

A fludarabine-based dose-reduced conditi

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome

✍ Kröger, N; Schetelig, J; Zabelina, T; Krüger, W; Renges, H; Stute, N; Schrum, J; 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 83 KB

A Pilot Study of T-Cell Depleted Allogen

A Pilot Study of T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation With Busulfan, Melphalan, and Fludarabine Conditioning Followed by Post Transplantation Donor Lymphocyte Infusions for Patients With Relapsed Multiple Myeloma and High-Risk Cytogenetics

✍ G. Koehne; H. Landau; H. Hassoun; A. Lesokhin; N. Lendvai; M. Rosenzweig; D.J. C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Relapse to prior autograft and chronic g

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

✍ Nicolaus Kröger; Jose A. Perez-Simon; Han Myint; Hans Klingemann; Avichai Shimon 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 289 KB

Favourable outcome for patients with mye

Favourable outcome for patients with myeloid disorders treated with fludarabine–melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies

✍ R. K. Malladi; A. J. Peniket; A. E. Norton; A. J. Campbell; G. P. Collins; J. Sa 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB